Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $20.71.

A number of brokerages have issued reports on STOK. JPMorgan Chase & Co. upped their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, March 26th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, April 11th. Canaccord Genuity Group upped their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Finally, Wedbush upped their price objective on Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th.

Stoke Therapeutics Stock Down 7.0 %

NASDAQ STOK opened at $11.03 on Wednesday. The firm has a market cap of $574.88 million, a price-to-earnings ratio of -4.65 and a beta of 0.76. The business has a 50-day moving average price of $9.68 and a 200-day moving average price of $6.40. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The firm had revenue of $2.80 million during the quarter, compared to analysts’ expectations of $3.70 million. Research analysts expect that Stoke Therapeutics will post -2.28 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the transaction, the chief executive officer now owns 69,350 shares of the company’s stock, valued at $423,035. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the transaction, the insider now directly owns 6,981 shares in the company, valued at approximately $33,508.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Insiders have sold a total of 3,632,741 shares of company stock valued at $41,983,115 over the last quarter. 12.30% of the stock is owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Lynx1 Capital Management LP acquired a new stake in shares of Stoke Therapeutics in the 3rd quarter worth $6,738,000. GSA Capital Partners LLP boosted its position in shares of Stoke Therapeutics by 514.7% in the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after purchasing an additional 291,443 shares in the last quarter. Birchview Capital LP boosted its position in shares of Stoke Therapeutics by 147.1% in the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after purchasing an additional 125,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Stoke Therapeutics by 9.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock worth $576,000 after purchasing an additional 12,478 shares in the last quarter. Finally, Trexquant Investment LP boosted its position in shares of Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock worth $503,000 after purchasing an additional 79,785 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.